Salute e Benessere | Diffusione Gratuita di Comunicati Stampa in inglese| Pubblica i tuoi comunicati con informazione.news

LIfT BioSciences appoints Antonin (Tony) de Fougerolles as Chairman of its Board…

LIfT BioSciences appoints Antonin (Tony) de Fougerolles as Chairman of its Board of DirectorsLondon,1 July 2024– LIfT BioSciences, ('LIfT' or 'the Company'), a rapidly emerging biotech company preparing to start clinical trials for its first-in-class allogeneic innate cell therapy, today announces the appointment of Antonin (Tony) de Fougerolles, PhD as Chairman of its Board.Tony brings over 25 years of biotech R&D experience in building out drug pipelines and bringing...

OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results…

OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab inAcute Lymphoblastic Leukemia in the Journal 'Blood'Nantes, France – July 1 st, 2024 – 7:30 am CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE)today announced the publication of an article on latest preclinical efficacy data on the use of its anti-IL-7 receptor (IL-7RA&io) antagonist Lusvertikimab (OSE-127) for the treatment of B- and T-Cell Acute Lymphoblastic...

XRP Healthcare: Helping to Transform HIV and AIDS Care with Innovative…

XRP Healthcare has announced a new initiative aimed at supporting individuals living with HIV and AIDS by providing them with access to theXRP Healthcare Prescription Savings Card. This powerful tool offers substantial discounts on essential medications, helping to alleviate the financial burden of managing chronic health conditions. Supporting People Living with HIV and AIDS HIV and AIDS continue to be significant global health challenges, with millions of individuals...

Valneva Receives Marketing Authorization in Europe for the World's First…

Saint Herblain (France), July 1, 2024–Valneva SE(Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Commission (EC) has granted marketing authorization in Europe for Valneva's single-dose vaccine, IXCHIQ ®, for the prevention of disease caused by the chikungunya virus in individuals 18 years of age and older. The approval was unanimously endorsed by Member States following a stringent assessment by the European Medicines Agency (EMA) 1...

FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by…

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in USPyzchiva® (ustekinumab-ttwe) is approved by FDA for all indications of reference medicineFDA granted provisional determination for interchangeability designation for Pyzchiva®Extends Sandoz immunology portfolio and further strengthens biosimilar position Expected to be among first wave of ustekinumab biosimilars to launch...

Addex Shareholders Approve All Resolutions at Annual General Meeting

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 1, 2024-Addex Therapeutics(SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that its shareholders approved, with a large majority, all proposals of the board of directors in its 2024 Annual General Meeting (AGM). The votes represented 33.79% of the company's outstanding capital.Addex shareholders approved...

Idorsia's JERAYGO (aprocitentan) approved in Europe as first and only ERA for…

Idorsia receives approval from the European Commission (EC) for JERAYGO ™(aprocitentan) as the first and only endothelin receptor antagonist (ERA) for the treatment of resistant hypertension.JERAYGO is a new oral antihypertensive therapy – the first in almost 40 years – that is working via a new therapeutic pathway.Allschwil, Switzerland – July 1, 2024Idorsia Ltd (SIX: IDIA) announced today that the European Commission (EC) has approved JERAYGO ™(aprocitentan) for the treatment of...

CBC-Backed Hasten Biopharmaceutical Announces Acquisition of 14 Celltrion Legacy…

According to the agreement, Hasten will own the Marketing Authorization Holder (MAH) rights for these 14 products in eight countries and regions, including South Korea*, Singapore, Thailand, Australia and China Hong Kong S.A.R. The deal not only enriches Hasten's product pipeline and supply chain system but also marks its business expansion across Pan-Asia region. As an innovative biopharmaceutical company focused on chronic diseases and critical care area, Hasten will expand its product…

ONWARD® Medical Obtains Debt Financing with up to €52.5 Million Secured Loan…

THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014)Runway Growth Capital LLC is a leading U.S.-based specialty finance lenderRelationship further strengthens Company's balance sheet ahead of pending FDA approval and expected Q4 launch of ARC-EX System in the U.S. EINDHOVEN, the Netherlands, June28, 2024(GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company...

Information on the total number of voting rights and shares

REGULATED INFORMATIONInformation on the total number of voting rights and sharesMont-Saint-Guibert (Belgium), June 28, 2024, 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares. Share capital: EUR 5,904,962.41 Total number of securities carrying voting rights: 34,373,015 (all ordinary...

Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024

thfloor, 75013 Paris, France.At the meeting, during which approximately 40% of shares were exercised, resolutions 1 through 28 were adopted and resolution 29 was rejected, consistent with the recommendations of the management.The detailed results of the vote and the resolutions are available on Cellectis' website: https://www.cellectis.com/en/investors/general-meetings/About Cellectis Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform...

Higher cantonal composition authority issues written court decision in respect…

Allschwil, Switzerland – June 28, 2024Idorsia Ltd (SIX: IDIA) today announced that it has received the written decision from the higher cantonal composition authority(obere kantonale Nachlassbehörde)(the Court) in respect to the approval of the amendments of the terms of its outstanding convertible bonds originally maturing on July 17, 2024 (ISIN: CH0426820350) decided at the bondholder meeting held on May 6, 2024.If no appeal is filed within the statutory period of 30 days, the...

Results of the Combined General Meeting of 28 June 2024

Lyon (France) and Cambridge (MA, US), 28 June 2024 - 5.45 pm CEST - PHAXIAM Therapeutics (Euronext: PHXM; FR0011471135), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections,announces the results of the shareholder vote following the Combined General Meeting held today, 28 June 2024, at the head office, located 60 avenue Rockefeller, 69008, Lyon.The shareholders approved all the resolutions on which the Board of Directors recommended a...

Pierre Fabre Laboratories announce granting of European marketing authorization…

The decision of the EC follows the favorable opinion issued on April 25 by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). It is based on the results of two pivotal, multicenter, double-blind, randomized phase 3 studies in adults with overactive bladder symptoms. Study RVT-901-3003 (EMPOWUR) evaluated the efficacy, tolerability, and safety of vibegron (at a dose of 75 mg per day) over 12 weeks compared to placebo and with tolterodine as a…

Zealand Pharma major shareholder announcement: Van Herk Investments

Company announcement – No. 38 / 2024 Zealand Pharma major shareholder announcement: Van Herk InvestmentsCopenhagen, Denmark, 28 June 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces the receipt on 28 June 2024 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholders:As...

Total number of shares and voting rights in Zealand Pharma at June 28, 2024

Company announcement – No. 37 / 2024 Total number of shares and voting rights in Zealand Pharma at June 28, 2024 Copenhagen, Denmark, June 28, 2024–Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at the end of...

Tiziana Receives $3.4 Million in Non-Dilutive Funding

here. Gabriele Cerrone, Chairman, acting CEO and founder of Tiziana Life Sciences commented, “Tiziana is pleased to receive $3.4 million in non-dilutive funding to support our ongoing Phase 2 trial of intranasal foralumab in non-active secondary progressive multiple sclerosis (na-SPMS) as well as our work in Alzheimer's Disease. We continue to explore all avenues to pursue further non-dilutive funding in the near term.” About Foralumab Activated T cells play an important role in the...

CO2 AI Launches First Solution to Compute Product Emissions at Scale

Traditional methods like manual Life Cycle Assessments (LCAs) are slow, inconsistent, and costly. According to the 2023 Carbon Survey by CO2 AI and Boston Consulting Group (BCG), only 38% of companies receive adequate product-level data from suppliers. Traditional methods like manual Life Cycle Assessments (LCAs) are slow, inconsistent, and costly. According to the 2023 Carbon Survey by CO2 AI and Boston Consulting Group (BCG), only 38% of companies receive adequate product-level data from...

IFPA Celebrates Success of the 7th IFPA Conference 2024

KFSHRC Performs Over 5,000 Successful Kidney Transplants

Bavarian Nordic Converts Existing Credit Facility into Sustainability-linked…

Groupe Casino sells over €200M of real estate assets to Tikehau Capital

Dawn Health and Merck are collaborating to support Growth Disorders care

Nyxoah Submits Fourth and Final Module in PMA Application for Genio to the US…

LIfT BioSciences appoints Antonin (Tony) de Fougerolles as Chairman of its Board…

OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results…

XRP Healthcare: Helping to Transform HIV and AIDS Care with Innovative…

Valneva Receives Marketing Authorization in Europe for the World's First…

FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by…

Addex Shareholders Approve All Resolutions at Annual General Meeting

Idorsia's JERAYGO (aprocitentan) approved in Europe as first and only ERA for…

CBC-Backed Hasten Biopharmaceutical Announces Acquisition of 14 Celltrion Legacy…

ONWARD® Medical Obtains Debt Financing with up to €52.5 Million Secured Loan…

Information on the total number of voting rights and shares

Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024

Higher cantonal composition authority issues written court decision in respect…

Results of the Combined General Meeting of 28 June 2024

Pierre Fabre Laboratories announce granting of European marketing authorization…

Zealand Pharma major shareholder announcement: Van Herk Investments

Total number of shares and voting rights in Zealand Pharma at June 28, 2024

Tiziana Receives $3.4 Million in Non-Dilutive Funding

CO2 AI Launches First Solution to Compute Product Emissions at Scale